Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

AMX0035 Extended Patients’ Survival By More Than 10 Months – ALS News Today,

AMX0035 significantly extended median survival by more than 10 months in the Phase 2 CENTAUR clinical trial, a new analysis indicates., AMX0035 significantly extended median survival by more than 10 months in the Phase 2 CENTAUR clinical trial, a new analysis indicates., Read More

Scroll to Top